# A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)

> **NCT05795465** · PHASE2 · RECRUITING · sponsor: **GEn1E Lifesciences** · enrollment: 52 (estimated)

## Conditions studied

- Respiratory Distress Syndrome, Acute

## Interventions

- **DRUG:** GEn-1124
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05795465
- **Lead sponsor:** GEn1E Lifesciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-04
- **Primary completion:** 2026-10
- **Final completion:** 2026-12
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05795465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05795465, "A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05795465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*